Development trends of the pharmaceutical market of oncological medicines for the treatment of prostate cancer in Ukraine in the context of the dynamics of incidence and mortality
Farmatsevtychnyi zhurnal · 26.05.2026 · (3) · 40-50
DOI: 10.32352/0367-3057.3.26.04 ↗Kurz gefasst
Fachartikel in der Zeitschrift Farmatsevtychnyi zhurnal, online erschienen am 26.05.2026. Verfasst von I. V. Bushueva und 2 weiteren Autor:innen. Die Arbeit nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The trend of increasing the incidence of prostate cancer and the frequency of complications caused by it (metastases to bones, lymph nodes, disorders of the urinary system, etc.) is observed more and more frequently in Ukraine. An urgent problem today is the development of new domestic effective drugs to combat this pathology. The purpose of the work is to establish a correlation between the dynamics of morbidity and mortality from prostate cancer, as well as to assess the current state of the domestic pharmaceutical market of drugs for the treatment of oncological pathologies of the prostate gland. Methods were used in the work: synthetic, analytical, information search, descriptive, generalization. The research materials were literary sources containing information on the market structure of oncological drugs for the treatment of prostate cancer, data from the National Cancer Registry of Ukraine for 2022–2024, and the State Register of Medicinal Products of Ukraine as of 2025. As of 2024, there were 55,343 patients with prostate cancer registered, which is about 13% of all cancers in men. Incidence is on a trend of 3.4% annually from 2010–2021, with some decline in 2022 to 10% due to the impact of war, but with a recovery in 2023. Dnipropetrovsk, Lviv, and Kyiv regions are the leaders in terms of the prevalence of the disease. Late diagnosis (III–IV stages) accounts for 37.2% of cases. About 120 trade names of drugs are registered for the treatment of RPZ, of which 79% are foreign-made. The leaders in the number of positions are France, Germany, and the USA. In terms of dosage forms, this market is heterogeneous and is represented by 15 dosage forms. According to the ATC classification, drugs for the treatment of prostate cancer are represented by groups: L02 (endocrine therapy, in particular antiandrogens L02BB ‒ bicalutamide, flutamide, enzalutamide; L02BX ‒ abiraterone), L01 (antineoplastic agents, in particular L01CD ‒ docetaxel, cabazitaxel), L01XK (PARP inhibitors ‒ olaparib). The assortment of anticancer drugs makes it possible to saturate this segment of the pharmaceutical market not only with imported drugs, but also to find opportunities for the creation and introduction of fundamentally new anticancer drugs into the domestic market.
Zitieren
APA
Bushueva, I. V., Parchenko, M. V., & Yerenko, O. K. (2026). Development trends of the pharmaceutical market of oncological medicines for the treatment of prostate cancer in Ukraine in the context of the dynamics of incidence and mortality. Farmatsevtychnyi zhurnal, 40-50. https://doi.org/10.32352/0367-3057.3.26.04
Vancouver
Bushueva IV, Parchenko MV, Yerenko OK. Development trends of the pharmaceutical market of oncological medicines for the treatment of prostate cancer in Ukraine in the context of the dynamics of incidence and mortality. Farmatsevtychnyi zhurnal. 2026:40-50. doi:10.32352/0367-3057.3.26.04
BibTeX
@article{Bushueva2026,
author = {Bushueva, I. V. and Parchenko, M. V. and Yerenko, O. K.},
title = {Development trends of the pharmaceutical market of oncological medicines for the treatment of prostate cancer in Ukraine in the context of the dynamics of incidence and mortality},
journal = {Farmatsevtychnyi zhurnal},
year = {2026},
number = {3},
pages = {40--50},
doi = {10.32352/0367-3057.3.26.04}
}
EUVIMED